ValuEngine upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, ValuEngine reports.
A number of other equities analysts have also recently weighed in on the company. Piper Jaffray Companies increased their price target on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an overweight rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Zacks Investment Research cut Deciphera Pharmaceuticals from a hold rating to a sell rating in a report on Monday, July 15th. BidaskClub cut Deciphera Pharmaceuticals from a sell rating to a strong sell rating in a report on Saturday, July 13th. Finally, Deutsche Bank assumed coverage on Deciphera Pharmaceuticals in a report on Thursday, July 18th. They set a buy rating and a $42.00 price target for the company. Three analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $41.00.
Shares of DCPH traded up $1.10 during midday trading on Thursday, reaching $23.47. The company had a trading volume of 2,361 shares, compared to its average volume of 278,758. Deciphera Pharmaceuticals has a 1-year low of $18.55 and a 1-year high of $41.00. The company has a market capitalization of $854.31 million, a PE ratio of -8.33 and a beta of 2.34. The business has a 50 day simple moving average of $22.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55.
Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its earnings results on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to analyst estimates of $20.00 million. On average, sell-side analysts predict that Deciphera Pharmaceuticals will post -4.69 EPS for the current year.
In other news, CFO Thomas Patrick Kelly sold 2,100 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 3,750 shares of company stock valued at $94,258. Company insiders own 7.02% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in Deciphera Pharmaceuticals by 73.6% during the 4th quarter. BlackRock Inc. now owns 1,173,245 shares of the company’s stock valued at $24,625,000 after acquiring an additional 497,427 shares during the period. Janus Henderson Group PLC boosted its holdings in Deciphera Pharmaceuticals by 2.1% during the 2nd quarter. Janus Henderson Group PLC now owns 675,707 shares of the company’s stock valued at $15,237,000 after acquiring an additional 14,028 shares during the period. Norges Bank purchased a new position in Deciphera Pharmaceuticals during the 4th quarter valued at about $6,974,000. Dimensional Fund Advisors LP purchased a new position in Deciphera Pharmaceuticals during the 4th quarter valued at about $4,337,000. Finally, Geode Capital Management LLC boosted its holdings in Deciphera Pharmaceuticals by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 166,904 shares of the company’s stock valued at $3,503,000 after acquiring an additional 27,157 shares during the period. Institutional investors own 58.87% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.
See Also: What is an investor looking for in an SEC filing?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.